Promethera, the Walloon biotech specialising in cell-based medicines and liver diseases has announced the opening of a new branch office in Tokyo.
This new office will strengthen the presence of Promethera in Japan, which has several Japanese investors among its shareholders (including Mitsui & Co. Global Investment, Mitsubishi UFJ Capital, Ltd., Cell Innovation Partners, L.P., Shibuya Corporation and Shinsei Corporate Investment as well as the South Korean LifeLiver Co.).
The international company has chosen to focus on business development, investor relations and the expansion of its business and products pipeline in Japan and on the Asian market.
"Today, we took another significant step as a global innovator in the liver disease space and are consistently pursuing our vision and strategy. Adding a local presence in Japan, in addition to our corporate headquarters and growing product development organization in Belgium, our operations and manufacturing centre of excellence in North Carolina (USA), as well as the recent acquisition of our new Swiss subsidiary, Baliopharm AG, represents a key milestone for Promethera in continuing to establish an international footprint,” commented John Tchelingerian, PhD, President & CEO of Promethera.
Promethera has also just completed a capital increase of 9.3 million euros. Another is scheduled in the coming months and the company is constantly developing. In 2019, the company plans to transfer its laboratories to the Biopark site in Gosselies.
A new, more substantial, capital increase is already being outlined for the coming months. As developments continue, and the laboratories are transferred to the Biopark site in Gosselies, still planned for 2019.
Sources: L'Echo, Promethera
